Norgesic (Orphenadrine Citrate, Paracetamol)

Orphenadrine citrate acts centrally as an anticholinergic agent. By blocking muscarinic receptors in the central nervous system, it reduces neuronal excitability and produces skeletal muscle relaxation, helping to alleviate muscle spasm and improve mobility in affected patients.

The dosage of Norgesic is individualized and set by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. Healthcare providers determine the appropriate strength, frequency, and duration according to current clinical guidelines.

Safety data for Norgesic in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Norgesic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Norgesic combines a central anticholinergic muscle relaxant (orphenadrine) with an analgesic (paracetamol), offering both spasm relief and pain control in a single tablet. Compared with single‑ingredient muscle relaxants, it may reduce the need for additional analgesics, but the combined profile also introduces the safety considerations of both components.

Norgesic tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Norgesic is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include severe allergic reactions such as anaphylaxis, hepatotoxicity especially in patients with pre‑existing liver disease, cardiac arrhythmias, hallucinations, and rare severe skin reactions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Norgesic should be avoided in patients with known hypersensitivity to orphenadrine, paracetamol, or any excipients, as well as in individuals with severe liver impairment, uncontrolled glaucoma, or significant cardiac conduction disorders. Caution is also advised for the elderly and those taking multiple anticholinergic or CNS‑depressant drugs.